Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18655892 | 0.76 | CNR2 (0.46) | CNR2CDK2EP300 | |
| SCHEMBL31470132 | 0.74 | CNR2 (0.47) | CNR2EP300PARP15PARP10PARP2 | |
| SCHEMBL26653945 | 0.74 | CNR2 (0.47) | CNR2EP300PARP15PARP10PARP2 | |
| SCHEMBL26654201 | 0.73 | CNR2 (0.46) | CNR2CDK2EP300CCNA2CCNA1 | |
| SCHEMBL26654219 | 0.73 | CNR2 (0.46) | CNR2CDK2EP300LRRK2 | |
| SCHEMBL30657964 | 0.73 | CNR2 (0.46) | CNR2CDK2EP300LRRK2 | |
| SCHEMBL14152124 | 0.72 | CNR2 (0.60) | CNR2 | |
| SCHEMBL30785769 | 0.72 | CNR2 (0.60) | CNR2 | |
| SCHEMBL31470086 | 0.71 | CNR2 (0.60) | CNR2 | |
| SCHEMBL14151695 | 0.71 | CNR2 (0.60) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
| WO-2017046318-A1 | TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | OAT, XDH, MAPT | CNR2 4598/4885CDK2 1378/4885EP300 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.